20:25 , Aug 21, 2019 |  BC Innovations  |  Distillery Therapeutics

Targeting CAD or DHODH to inhibit pyrimidine synthesis for glioblastoma

DISEASE CATEGORY: Cancer INDICATION: Brain cancer Blocking pyrimidine synthesis via inhibition of CAD or DHODH, an enzyme downstream CAD, could treat glioblastoma. In patients, high tumor expression of a pyrimidine metabolism gene signature was associated...
20:54 , May 20, 2019 |  BC Innovations  |  Distillery Therapeutics

Aubagio and other DHODH inhibitors as epilepsy therapies

DISEASE CATEGORY: Neurology INDICATION: Epilepsy Patient sample, cell culture and mouse studies suggest inhibiting DHODH could help treat epilepsy. Metabolic modeling of transcriptome data from the cortex and hippocampus of epilepsy patients and two rat...
23:18 , Feb 1, 2019 |  BioCentury  |  Product Development

Year of the lion

With three data readouts coming in 2019, Aslan Pharmaceuticals Ltd. is hoping this will be the year it starts to reap the benefits of its 2012 strategy rethink, giving the biotech more options for advancing...
01:35 , Feb 1, 2019 |  BC Week In Review  |  Company News

Ahead of 2019 milestones, Aslan reduces headcount, operating costs

Aslan Pharmaceuticals Ltd. (TPEx:6497; NASDAQ:ASLN) said late Jan. 29 it will reduce headcount by 30% and slash operating costs by 50%. The restructuring will help support Aslan well into 2020 as it focuses operations on...
23:00 , Jan 29, 2019 |  BC Extra  |  Company News

Aslan to reduce headcount, operating costs to support upcoming milestones

Aslan Pharmaceuticals Ltd. (TPEx:6497; NASDAQ:ASLN) said late Tuesday it will reduce headcount by 30% and slash operating costs by 50%. The restructuring will help support Aslan well into 2020 as it focuses operations on its...
22:56 , Apr 10, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Melanoma Cell culture and mouse studies identified p53-activating tetrahydroindazole-based DHODH inhibitors that could help treat melanoma. Screening of a small molecule library in human melanoma cell line-based assays of p53-dependent transcription, followed by chemical...
19:50 , Aug 18, 2017 |  BC Week In Review  |  Company News

Aslan and Academia Sinica combine ASLAN003 and varlitinib in animal models

Aslan Pharmaceuticals Ltd. (TPEx:6497) and Academia Sinica (Taipei, Taiwan) partnered to evaluate the the combination of varlitinib ( ASLAN001 ) and ASLAN003 in animal models for gastric, colorectal and lung cancers. The partners said the...
19:57 , Mar 10, 2017 |  BC Week In Review  |  Company News

Aslan, CSI, NCIS deal

Aslan, CSI and NCIS partnered to develop ASLAN003 to treat hematologic cancers as monotherapy and in combination with other undisclosed agents. Aslan is developing the oral dihydroorotate dehydrogenase (DHODH) inhibitor to treat cancer, including acute...
08:00 , Jan 18, 2016 |  BC Week In Review  |  Company News

Almirall, Aslan deal

Aslan and Almirall expanded a 2012 deal to grant Aslan exclusive, worldwide rights to develop and commercialize ASLAN003 ( LAS186323 ) for all non-topical and non-dermatological indications, including cancer. The small molecule oral dihydroorotate dehydrogenase...
07:00 , Apr 29, 2013 |  BC Week In Review  |  Clinical News

ASLAN003: Phase I start

Next month, Aslan will begin a double-blind, placebo-controlled, Singaporean Phase I trial to evaluate multiple ascending-doses of ASLAN003 in healthy volunteers. Last May, Almirall granted Aslan exclusive, worldwide rights to the compound. Aslan will conduct...